• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型吡咯霉素 MP1 单独及联合替西罗莫司在 MYCN 扩增化疗耐药神经母细胞瘤细胞系中的作用。

Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.

机构信息

Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, 986145 Nebraska Medical Center, Omaha, NE, 68198-6145, USA.

College of Medicine, Division of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA.

出版信息

BMC Cancer. 2019 Aug 27;19(1):837. doi: 10.1186/s12885-019-6033-2.

DOI:10.1186/s12885-019-6033-2
PMID:31455317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6712804/
Abstract

BACKGROUND

The activity of MP1, a pyrrolomycin, was studied in MYCN amplified neuroblastoma (NB) alone and combined with temsirolimus (TEM).

METHODS

Activity of MP1 was tested in MYCN amplified (BE-2c, IMR) and non amplified (SKN-AS) NB cells. The effect of MP1 on MYCN, MCL-1, cleaved PARP, LC3II/LC3I, bcl-2, BAX, and BRD-4 were determined by western blot and RNAseq. The effect of MP1 on metabolism, mitochondrial morphology, and cell cycle was determined. Toxicology and efficacy of MP1 plus TEM were evaluated.

RESULTS

The IC of MP1 was 0.096 μM in BE-2c cells compared to 0.89 μM in IMR, and >50 μM in SKN-AS. The IC of MP1 plus TEM in BE-2c cells was 0.023 μM. MP1 inhibited metabolism leading to quiescence and produced a decline in cell cycle S-phase. Electron microscopy showed cristae loss and rounding up of mitochondria. Gene and protein expression for MYCN and MCL-1 declined while LCII and cleaved PARP increased. Protein expression of BAX, bcl-2, and BRD-4 were not significantly changed after MP1 treatment. The in-vivo concentrations of MP1 in blood and tumor were sufficient to produce the biologic effects seen in-vitro. MP1 plus TEM produced a complete response in 3 out of 5 tumor bearing mice. In a second mouse study, the combination of MP1 and TEM slowed tumor growth compared to control.

CONCLUSIONS

MP1 has a potent inhibitory effect on the viability of MYCN amplified NB. Inhibition of metabolism by MP1 induced quiescence and autophagy with a favorable toxicology and drug distribution profile. When combined with TEM anti-tumor activity was potentiated in-vitro and in-vivo.

摘要

背景

吡咯霉素 MP1 的活性在 MYCN 扩增神经母细胞瘤(NB)中进行了研究,单独使用以及与替西罗莫司(TEM)联合使用。

方法

在 MYCN 扩增(BE-2c、IMR)和非扩增(SKN-AS)NB 细胞中测试了 MP1 的活性。通过 Western blot 和 RNAseq 确定 MP1 对 MYCN、MCL-1、裂解 PARP、LC3II/LC3I、bcl-2、BAX 和 BRD-4 的影响。测定 MP1 对代谢、线粒体形态和细胞周期的影响。评估 MP1 加 TEM 的毒性和疗效。

结果

MP1 在 BE-2c 细胞中的 IC 为 0.096 μM,而在 IMR 中的 IC 为 0.89 μM,在 SKN-AS 中的 IC 大于 50 μM。MP1 加 TEM 在 BE-2c 细胞中的 IC 为 0.023 μM。MP1 抑制代谢导致静止,并导致细胞周期 S 期减少。电子显微镜显示嵴丢失和线粒体圆化。MYCN 和 MCL-1 的基因和蛋白表达下降,而 LCII 和裂解 PARP 增加。MP1 处理后,BAX、bcl-2 和 BRD-4 的蛋白表达没有明显变化。血液和肿瘤中的 MP1 浓度足以产生体外观察到的生物学效应。MP1 加 TEM 在 5 只荷瘤小鼠中有 3 只产生完全反应。在第二项小鼠研究中,与对照组相比,MP1 和 TEM 的联合使用减缓了肿瘤生长。

结论

MP1 对 MYCN 扩增 NB 的活力具有很强的抑制作用。MP1 抑制代谢诱导静止和自噬,具有良好的毒理学和药物分布特征。当与 TEM 联合使用时,在体外和体内均增强了抗肿瘤活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/418a8f7bdfa6/12885_2019_6033_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/9fec33eeb971/12885_2019_6033_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/4d08de445a58/12885_2019_6033_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/1f2f4951775c/12885_2019_6033_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/72ca88719cf5/12885_2019_6033_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/e330de7ffba5/12885_2019_6033_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/cd515ee8bf02/12885_2019_6033_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/72a865cdf00b/12885_2019_6033_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/418a8f7bdfa6/12885_2019_6033_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/9fec33eeb971/12885_2019_6033_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/4d08de445a58/12885_2019_6033_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/1f2f4951775c/12885_2019_6033_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/72ca88719cf5/12885_2019_6033_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/e330de7ffba5/12885_2019_6033_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/cd515ee8bf02/12885_2019_6033_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/72a865cdf00b/12885_2019_6033_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/451d/6712804/418a8f7bdfa6/12885_2019_6033_Fig8_HTML.jpg

相似文献

1
Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.新型吡咯霉素 MP1 单独及联合替西罗莫司在 MYCN 扩增化疗耐药神经母细胞瘤细胞系中的作用。
BMC Cancer. 2019 Aug 27;19(1):837. doi: 10.1186/s12885-019-6033-2.
2
Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.抑制 MYCN 和 mTOR 信号对神经母细胞瘤的协同疗效。
BMC Cancer. 2021 Sep 26;21(1):1061. doi: 10.1186/s12885-021-08782-9.
3
Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513.用抗疟臭氧化物OZ513治疗化疗耐药的神经母细胞瘤细胞系。
BMC Cancer. 2016 Nov 8;16(1):867. doi: 10.1186/s12885-016-2872-2.
4
Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.节律性拓扑替康通过诱导衰老在体外和体内抑制MYCN扩增的神经母细胞瘤细胞的肿瘤生长。
Oncotarget. 2016 Jan 19;7(3):3571-86. doi: 10.18632/oncotarget.6527.
5
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.BET 抑制剂与 Aurora A 激酶抑制剂在 MYCN 扩增神经母细胞瘤中的协同作用因功能性 TP53 而增强。
Neoplasia. 2021 Jun;23(6):624-633. doi: 10.1016/j.neo.2021.05.003. Epub 2021 Jun 7.
6
GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.GX15-070(Obatoclax),一种 Bcl-2 家族蛋白抑制剂,可诱导神经母细胞瘤细胞凋亡和抗细胞凋亡自噬,并增加化疗敏感性。
BMC Cancer. 2019 Oct 29;19(1):1018. doi: 10.1186/s12885-019-6195-y.
7
Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[F]FGln PET Imaging.通过 4-[F]FGln PET 成像对 MYCN 扩增神经母细胞瘤进行代谢评估。
Mol Imaging Biol. 2019 Dec;21(6):1117-1126. doi: 10.1007/s11307-019-01330-9.
8
A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.一种新型 MYCN 特异性抗原寡核苷酸可使线粒体失活并抑制 MYCN 扩增神经母细胞瘤的肿瘤生长。
Cancer Res. 2019 Dec 15;79(24):6166-6177. doi: 10.1158/0008-5472.CAN-19-0008. Epub 2019 Oct 15.
9
Venetoclax-based Rational Combinations are Effective in Models of -amplified Neuroblastoma.基于 Venetoclax 的合理联合在 -amplified 神经母细胞瘤模型中有效。
Mol Cancer Ther. 2021 Aug;20(8):1400-1411. doi: 10.1158/1535-7163.MCT-20-0710. Epub 2021 Jun 4.
10
The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.小分子 Bcl-2/Mcl-1 抑制剂 TW-37 在神经母细胞瘤细胞系中表现出单药细胞毒性。
BMC Cancer. 2019 Mar 18;19(1):243. doi: 10.1186/s12885-019-5439-1.

引用本文的文献

1
Insights into Metabolic Reprogramming in Tumor Evolution and Therapy.肿瘤发生发展及治疗中代谢重编程的见解
Cancers (Basel). 2024 Oct 17;16(20):3513. doi: 10.3390/cancers16203513.
2
Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.海洋吡咯衍生物 MP1 作为一种新型的抗癌药物,用于治疗 3 组 MYC 扩增型髓母细胞瘤。
J Exp Clin Cancer Res. 2024 Jan 11;43(1):18. doi: 10.1186/s13046-024-02944-w.
3
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

本文引用的文献

1
Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.双重 BRD4 和 AURKA 抑制对 MYCN 扩增和非扩增神经母细胞瘤具有协同作用。
Neoplasia. 2018 Oct;20(10):965-974. doi: 10.1016/j.neo.2018.08.002. Epub 2018 Aug 25.
2
Metformin as an Anticancer Agent.二甲双胍作为一种抗癌剂。
Trends Pharmacol Sci. 2018 Oct;39(10):867-878. doi: 10.1016/j.tips.2018.07.006. Epub 2018 Aug 24.
3
Metformin and cancer: An existing drug for cancer prevention and therapy.二甲双胍与癌症:一种用于癌症预防和治疗的现有药物。
合成杂环衍生物作为激酶抑制剂,用于神经母细胞瘤的治疗研究。
Molecules. 2021 Nov 23;26(23):7069. doi: 10.3390/molecules26237069.
4
Analogs of Marinopyrrole A Show Enhancement to Observed Potency against Acute Toxoplasma gondii Infection.Marinopyrrole A 类似物对急性弓形体感染的观察效力增强。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0079421. doi: 10.1128/AAC.00794-21. Epub 2021 Oct 18.
5
Assessment of Tissue Distribution and Metabolism of MP1, a Novel Pyrrolomycin, in Mice Using a Validated LC-MS/MS Method.使用经过验证的液相色谱-串联质谱法评估新型吡咯霉素MP1在小鼠体内的组织分布和代谢
Molecules. 2020 Dec 13;25(24):5898. doi: 10.3390/molecules25245898.
6
New Synthetic Nitro-Pyrrolomycins as Promising Antibacterial and Anticancer Agents.新型合成硝基吡咯霉素有望成为抗菌和抗癌药物。
Antibiotics (Basel). 2020 May 30;9(6):292. doi: 10.3390/antibiotics9060292.
Oncol Lett. 2018 Jan;15(1):683-690. doi: 10.3892/ol.2017.7412. Epub 2017 Nov 14.
4
The Expanding World of N-MYC-Driven Tumors.N-MYC 驱动肿瘤的不断扩展的世界。
Cancer Discov. 2018 Feb;8(2):150-163. doi: 10.1158/2159-8290.CD-17-0273. Epub 2018 Jan 22.
5
Using droplet digital PCR to analyze and copy number in plasma from patients with neuroblastoma.使用液滴数字PCR分析神经母细胞瘤患者血浆中的拷贝数。
Oncotarget. 2017 Jul 7;8(49):85234-85251. doi: 10.18632/oncotarget.19076. eCollection 2017 Oct 17.
6
MYC and tumor metabolism: chicken and egg.MYC与肿瘤代谢:因果难定。
EMBO J. 2017 Dec 1;36(23):3409-3420. doi: 10.15252/embj.201796438. Epub 2017 Nov 10.
7
Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.直接靶向作用于线粒体离子通道选择性杀死体内肿瘤细胞。
Cancer Cell. 2017 Apr 10;31(4):516-531.e10. doi: 10.1016/j.ccell.2017.03.003.
8
Metformin: An anti-diabetic drug to fight cancer.二甲双胍:一种用于抗癌的抗糖尿病药物。
Pharmacol Res. 2016 Nov;113(Pt A):675-685. doi: 10.1016/j.phrs.2016.10.006. Epub 2016 Oct 5.
9
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.抑制mTOR激酶会使MYCN不稳定,是治疗MYCN依赖性肿瘤的一种潜在疗法。
Oncotarget. 2016 Sep 6;7(36):57525-57544. doi: 10.18632/oncotarget.10544.
10
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.利用MYCN扩增神经母细胞瘤的凋亡启动状态开发强效且特异性的靶向治疗组合。
Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.